Nobligan Retard (Tramadol Hydrochloride)

Tramadol Hydrochloride, the active ingredient in Nobligan Retard, is an opioid analgesic presented as an extended‑release tablet for oral use. It treats moderate to severe acute pain and chronic pain requiring opioid therapy in adult patients, providing sustained analgesia through a controlled‑release formulation.

GNH USA supplies Nobligan Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including acute‑care and surgical settings.

Nobligan Retard (tramadol) is used for pain management within the opioid analgesic pathway.

- Moderate to severe acute pain: provides rapid analgesia for postoperative or trauma‑related pain. - Chronic musculoskeletal pain: offers sustained relief for conditions such as osteoarthritis when opioid therapy is indicated. - Cancer‑related pain: contributes to multimodal analgesia for patients requiring opioid treatment. - Neuropathic pain: may be incorporated into combination therapy for certain neuropathic pain states.

Tramadol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Dizziness: light‑headedness or unsteady sensation. - Constipation: reduced bowel movements. - Headache: mild to moderate pain in the head. - Somnolence: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Seizures: convulsive episodes, especially at high doses. - Respiratory depression: slowed breathing that can be life‑threatening. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with serotonergic agents. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hypotension: marked drop in blood pressure.

Before prescribing Nobligan Retard, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess pain severity and opioid requirement: ensure the indication justifies opioid therapy. - Review history of substance misuse: avoid in patients with known opioid dependence. - Monitor respiratory function: especially in the elderly, obese, or those with pulmonary disease. - Caution in uncontrolled epilepsy: tramadol can lower seizure threshold. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Tramadol interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - SSRIs or SNRIs: increased serotonin syndrome potential. - CNS depressants (e.g., benzodiazepines, alcohol): additive respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise tramadol plasma levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce analgesic efficacy. - Anticoagulants (e.g., warfarin): possible enhanced bleeding risk.